Novel agents in classical Hodgkin lymphoma

References

• Surveillance, Epidemiology, and End Results (SEER) Program (http://seer.cancer.gov/data/); 2015.
   Google Scholar
• Behringer K, Goergen H, Hitz F, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet. 2015;385:1418–1427.
   PubMed Web of Science ®Google Scholar
• Von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. JCO. 2012;30:907–913.
   PubMed Web of Science ®Google Scholar
• Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548–4554.
   PubMed Web of Science ®Google Scholar
• Borchmann S, von Tresckow B, Engert A. Current developments in the treatment of early-stage classical Hodgkin lymphoma. Curr Opin Oncol. 2016;28:377–383.
   PubMed Web of Science ®Google Scholar
• Van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175:1007–1017.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373:2499–2511.
   PubMed Web of Science ®Google Scholar
• Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin study group HD13 to HD15 Trials. JCO. 2013;31:231–239.
   PubMed Web of Science ®Google Scholar
• Kreissl S, Mueller H, Goergen H, et al. Cancer-related fatigue in patients with and survivors of Hodgkin’s lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol. 2016;17:1453–1462.
   PubMed Web of Science ®Google Scholar
• Behringer K, Goergen H, Müller H, et al. Cancer-related fatigue in patients with and survivors of Hodgkin lymphoma: the impact on treatment outcome and social reintegration. J Clin Oncol. 2016;34:4329–4337.
   PubMed Web of Science ®Google Scholar
• Böll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127:2189–2192.
   PubMed Web of Science ®Google Scholar
• Böll B, Görgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin study group HD10 and HD11 trials. JCO. 2013;31:1522–1529.
   PubMed Web of Science ®Google Scholar
• Böll B, Goergen H, Arndt N, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. JCO. 2013;31:4431–4441.
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812–1821.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171–179.
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30:2183–2189.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:1236–1243.
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14:1348–1356.
   PubMed Web of Science ®Google Scholar
• Phase 3 frontline therapy trial in patients with advanced classical Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT01712490; 2016.
   Google Scholar
• Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284–292.
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second–line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21:2136–2140.
   PubMed Web of Science ®Google Scholar
• Phase I/II feasibility study combining brentuximab vedotin with second line salvage chemotherapy (DHAP) in Hodgkin lymphoma patients – full text view – ClinicalTrials.gov Identifier: NCT02280993; 2016.
   Google Scholar
• Garcia-Sanz R, Sureda A, Gonzalez AP, et al. Brentuximab vedotin plus ESHAP (BRESHAP) is a highly effective combination for inducing remission in refractory and relapsed Hodgkin lymphoma patients prior to autologous stem cell transplant: a trial of the Spanish Group of lymphoma and bone marrow Transplantation. Blood. 2016;128: 1109.
   Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–1862.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126:2798–2804.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120:560–568.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Bociek G, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;126:3982.
   Web of Science ®Google Scholar
• Yasenchak CA, Forero-Torres A, Cline-Burkhardt VJM, et al. Brentuximab vedotin in combination with dacarbazine or bendamustine for frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: interim results of a multi-cohort phase 2 study. Blood. 2015;126:23.
   Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134–144.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–319.
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. JCO. 2016;34:JCO673467.
   Google Scholar
• Munakata W, Ohashi K, Yamauchi N, et al. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol. 2017;105:383–386.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755.
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–1294.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Zinzani PL, Fanale MA, et al. Pembrolizumab in relapsed/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 keynote-087 study. Blood. 2016;128:1107.
   Web of Science ®Google Scholar
• Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2011;12:1222–1228.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27:1628–1636.
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. JCO. 2012;30:2197–2203.
   PubMed Web of Science ®Google Scholar
• Kirschbaum MH, Goldman BH, Zain JM, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma. 2012;53:259–262.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Valdez BC, Thall PF, et al. Vorinostat combined with high-dose gemcitabine, busulfan, and melphalan with autologous stem cell transplantation in patients with refractory lymphomas. Biol Blood Marrow Transplant. 2015;21:1914–1920.
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–3277.
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34:2690–2697.
   PubMed Web of Science ®Google Scholar
• Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. JCO. 2012;30:4161–4167.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kang HJ, Shin D-Y, et al. Pilot study of ruxolitinib in relapsed or refractory Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2014;124:4443.
   Google Scholar
• JAK– inhibition in recurrent classical Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02164500; 2016.
   Google Scholar
• Jachimowicz RD, Borchmann S, Rothe A. Multi-specific antibodies for cancer immunotherapy. BioDrugs. 2014;28:331–343.
   PubMed Web of Science ®Google Scholar
• Kumar A, Blum KA, Fung HC, et al. A phase 1 dose-escalation study of XmAb® 2513 in patients with relapsed or refractory Hodgkin lymphoma. Br J Haematol. 2015;168:902–904.
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Topp MS, et al. A phase I study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:4024–4031.
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Younes A. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther. 2006;6:131–140.
   PubMed Web of Science ®Google Scholar
• Oki Y, Fanale M, Romaguera J, et al. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol. 2015;171:463–470.
   PubMed Web of Science ®Google Scholar
• Guidetti A, Carlo-Stella C, Locatelli SL, et al. Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases. Clin Cancer Res. 2014;20:5641–5651.
   PubMed Web of Science ®Google Scholar
• Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010;85:320–324.
   PubMed Web of Science ®Google Scholar
• Johnston PB, Pinter-Brown L, Rogerio J, et al. Everolimus for relapsed/refractory classical Hodgkin lymphoma: multicenter, open-label, single-arm, phase 2 study. Blood. 2012;120:2740.
   Web of Science ®Google Scholar
• Oki Y, Buglio D, Fanale M, et al. Phase I Study of panobinostat plus everolimus in patients with relapsed or refractorylymphoma. Clin Cancer Res. 2013;19:6882–6890.
   PubMed Web of Science ®Google Scholar
• Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11:181–187.
   PubMed Web of Science ®Google Scholar
• Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1679–1687.
   PubMed Web of Science ®Google Scholar
• Wang C, Wu Z, Wang Y, et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin’s lymphoma: an open-label phase I trial. Clin Cancer Res. 2017;23:1156–1166.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein–Barr virus latent membrane proteins. JCO. 2014;32:798–808.
   PubMed Web of Science ®Google Scholar
• Boll B, Borchmann P, Topp MS, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol. 2010;148:480–482.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118:5119–5125.
   PubMed Web of Science ®Google Scholar
• Rueda A, García-Sanz R, Pastor M, et al. A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. Acta Oncol (Madr). 2015;54:933–938.
   PubMed Web of Science ®Google Scholar
• Lamprecht B, Walter K, Kreher S, et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med. 2010;16:571–579.
   PubMed Web of Science ®Google Scholar
• Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812–1826.
   PubMed Web of Science ®Google Scholar
• Von Tresckow B, Morschhauser F, Ribrag V, et al. An open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma. Clin Cancer Res. 2015;21:1843–1850.
   PubMed Web of Science ®Google Scholar
• Oki Y, Copeland A, Hagemeister F, et al. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. 2012;119:2171–2172.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Schnell R, Diehl V, et al. New drugs in the treatment of Hodgkin’s disease. Ann Oncol off J Eur Soc Med Oncol. 1998;9:S103–S108.
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Hamlin PA, Perales MA, et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013;31:456–460.
   PubMed Web of Science ®Google Scholar
• Fanale M, Assouline S, Kuruvilla J, et al. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol. 2014;164:258–265.
   PubMed Web of Science ®Google Scholar
• Smith SM, Schöder H, Johnson JL, et al. The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: cancer and leukemia group B 50602 (Alliance). Leuk Lymphoma. 2013;54:1405–1410.
   PubMed Web of Science ®Google Scholar
• Everolimus in combination with DHAP in patients with relapsed or refractory Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT01453504; 2016.
   Google Scholar
• HD21 for advanced stages – full text view – ClinicalTrials.gov Identifier: NCT02661503; 2016.
   Google Scholar
• A Phase II study of brentuximab vedotin (BV) in the treatment of elderly Hodgkin lymphoma (HL) patients at first relapse or with primary refractory disease. Full text view – ClinicalTrials.gov Identifier: NCT02227433; 2016.
   Google Scholar
• Mocetinostat (MGCD0103) plus brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02429375; 2016.
   Google Scholar
• Study of rituximab and brentuximab vedotin for relapsed classical Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT01900496; 2016.
   Google Scholar
• Brentuximab vedotin and bendamustine for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) – full text view – ClinicalTrials.gov Identifier: NCT01657331; 2016.
   Google Scholar
• Brentuximab vedotin plus AD in non-bulky limited stage Hodgkin lymphoma. ClinicalTrials.gov Identifier: NCT02505269; 2016.
   Google Scholar
• Everolimus and brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02254239; 2016.
   Google Scholar
• A pilot trial of AVD and brentuximab vedotin (SGN-35) in the treatment of stage III–IV HIV–associated Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02298257; 2016.
   Google Scholar
• Brentuximab vedotin, ifosfamide, carboplatin, and etoposide in treating patients with relapsed or refractory Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02227199; 2016.
   Google Scholar
• Ibrutinib and brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02744612; 2016.
   Google Scholar
• Brentuximab vedotin and combination chemotherapy in treating patients with stage II–IV HIV–associated Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT01771107; 2016.
   Google Scholar
• Brentuximab vedotin in refractory/relapsed Hodgkin lymphoma treated by ICE – full text view – ClinicalTrials.gov Identifier: NCT02686346; 2016.
   Google Scholar
• Brentuximab vedotin associated with chemotherapy in untreated patients with Hodgkin lymphoma. ClinicalTrials.gov Identifier: NCT02292979; 2015.
   Google Scholar
• Brentuximab for newly diagnosed Hodgkin disease – full text view – ClinicalTrials.gov Identifier: NCT02398240; 2016.
   Google Scholar
• Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02191930; 2016.
   Google Scholar
• Brentuximab vedotin as consolidation treatment in patients with stage I/II HL and PET positivity after 2 cycles of ABVD. ClinicalTrials.gov Identifier: NCT02298283; 2016.
   Google Scholar
• Brentuximab vedotin combined with AVD chemotherapy and involved-site radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma. ClinicalTrials.gov Identifier: NCT01868451; 2016.
   Google Scholar
• Immunotherapy following reduced intensity conditioning and allogeneic stem cell transplant for poor risk CD30+ Hodgkin lymphoma patients – full text view – ClinicalTrials.gov Identifier: NCT02098512; 2016.
   Google Scholar
• A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s lymphoma and CD30+ peripheral T-cell lymphoma in first salvage setting: the BBV regimen – full text view – ClinicalTrials.gov Identifier: NCT02499627; 2016.
   Google Scholar
• Hodgkin lymphoma treatment with adcetris and levact in the old patient – full text view – ClinicalTrials.gov Identifier: NCT02467946; 2016.
   Google Scholar
• Study of REGN2810 and REGN1979 in patients with lymphoma or acute lymphoblastic leukemia – full text view – ClinicalTrials.gov Identifier: NCT02651662; 2016.
   Google Scholar
• Avelumab in patients with previously treated advanced stage classical Hodgkin’s lymphoma (JAVELIN HODGKINS) – full text view – ClinicalTrials.gov Identifier: NCT02603419; 2016.
   Google Scholar
• Safety & efficacy study of combination of pembrolizumab and lenalidomide, in patients with relapsed non-Hodgkin and Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02875067; 2016.
   Google Scholar
• Pilot study of pembrolizumab treatment for disease relapse after allogeneic stem cell transplantation – full text view – ClinicalTrials.gov Identifier: NCT02981914; 2016.
   Google Scholar
• Pembrolizumab in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms – full text view – ClinicalTrials.gov Identifier: NCT02595866; 2016.
   Google Scholar
• ACP-196 (acalabrutinib) in combination with pembrolizumab, for treatment of hematologic malignancies – full text view – ClinicalTrials.gov Identifier: NCT02362035; 2016.
   Google Scholar
• A study of brentuximab vedotin combined with nivolumab for relapsed or refractory Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02572167; 2016.
   Google Scholar
• Ibrutinib and nivolumab in treating patients with relapsed or refractory classical Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02940301; 2016.
   Google Scholar
• Ipilimumab, nivolumab, and brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT01896999; 2016.
   Google Scholar
• Nivolumab and brentuximab vedotin in treating older patients with untreated Hodgkin lymphoma. ClinicalTrials.gov Identifier: NCT02758717. 2016.
   Google Scholar
• A study of the safety, tolerability, and efficacy of epacadostat administered in combination with nivolumab in select advanced cancers (ECHO-204) – full text view – ClinicalTrials.gov Identifier: NCT02327078; 2016.
   Google Scholar
• Nivolumab with or without ipilimumab in treating younger patients with recurrent or refractory solid tumors or sarcomas – full text view – ClinicalTrials.gov Identifier: NCT02304458; 2016.
   Google Scholar
• Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143–153.
   PubMed Web of Science ®Google Scholar
• Study of the combination of AFM13 and pembrolizumab in patients with relapsed or refractory classical Hodgkin lymphoma – full text view – ClinicalTrials.gov Identifier: NCT02665650; 2016.
   Google Scholar
• Study of pembrolizumab (MK-3475) vs. brentuximab vedotin in participants with relapsed or refractory classical Hodgkin lymphoma (MK-3475-204/KEYNOTE-204) – full text view – ClinicalTrials.gov Identifier: NCT02684292; 2016.
   Google Scholar
• Nivolumab with Epstein–Barr virus specific T cells (EB-VSTS), relapsed/refractory EBV positive lymphoma (PREVALE) – full text view – ClinicalTrials.gov Identifier: NCT02973113; 2016.
   Google Scholar
• A study of CA-170 (Oral PD-L1, PD-L2 and VISTA checkpoint antagonist) in patients with advanced tumors and lymphomas – full text view – ClinicalTrials.gov Identifier: NCT02812875; 2016.
   Google Scholar
• Pembrolizumab after ASCT for Hodgkin lymphoma and DLBCL – full text view – ClinicalTrials.gov Identifier: NCT02362997; 2016.
   Google Scholar
• A study of nivolumab + brentuximab vedotin in children, adolescents, and young adults with classic Hodgkin lymphoma (cHL) after failure of first line therapy, followed by brentuximab vedotin + bendamustine for participants with a suboptimal response – full text view – ClinicalTrials.gov Identifier: NCT02927769; 2017.
   Google Scholar